Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar 30;11(4):619.
doi: 10.3390/diagnostics11040619.

Multicentre Evaluation of Hepika Test Clinical Accuracy in Diagnosing HPV-Induced Cancer and Precancerous Lesions of the Uterine Cervix

Daniela Gustinucci  1 , Lucia Ciccocioppo  2 , Luigi Coppola  3 , Giovanni Negri  4 , Gianfranco Zannoni  5 , Basilio Passamonti  1 , Elena Cesarini  1 , Ciro Ianzano  2 , Tiziana Andreano  6 , Anjuta Pireddu  7 , Paolo Giorgi-Rossi  8
Affiliations

Multicentre Evaluation of Hepika Test Clinical Accuracy in Diagnosing HPV-Induced Cancer and Precancerous Lesions of the Uterine Cervix

Daniela Gustinucci et al. Diagnostics (Basel). .

Abstract

Objective: To evaluate the clinical accuracy of Hepika test to identify cancer/precancerous lesions of the uterine cervix.

Materials and methods: A multicentre retrospective study was carried out in 2018 and included 330 liquid-based cytology samples from three Italian centres of women aged 25-64 who had been tested for the human papillomavirus (HPV) and whose histology or follow-up outcome was known. Hepika is an enzyme-linked immunosorbent assay (ELISA) targeting the protein complexes E6#p53 and E7#pRb. After excluding samples without sufficient residual material, the clinical accuracy of Hepika test was evaluated in 274 samples: adenocarcinoma (ADC) (4), squamous cell carcinoma (SCC) (7), adenocarcinoma in situ (AIS) (1), cervical intraepithelial neoplasia (CIN) grade 3 (60), CIN2 (51), CIN1 (34), and negative histology (117). Association, sensitivity, and specificity for carcinoma, CIN3+ and CIN2+ are reported.

Results: Positive Hepika test was associated with a high probability of carcinoma (odds ratio (DOR) = 33.68, 95% confidence interval (CI) 7.0-163.1); sensitivity was 81.8%, specificity, 88.2%. A positive Hepika test showed a weaker association with CIN3+ lesions (DOR = 3.5; 95% CI 1.75-6.99) and lower sensitivity (27.8%).

Conclusion: The Hepika test was found to be an accurate biomarker for HPV-induced cervical carcinoma. Population-based prospective studies are needed to confirm the clinical usefulness of the Hepika test in the differential diagnosis of HPV-induced invasive lesions.

Keywords: CIN; HPV; Hepika; cancer; carcinoma; precancerous lesion; tumor biomarker; uterine cervix.

PubMed Disclaimer

Conflict of interest statement

The other authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Samples of the study and relative testing results. (Abbreviations: HG: high grade; LG: low grade).
Figure 2
Figure 2
Mean size of residual liquid by histology.
Figure 3
Figure 3
Estimated mean values of total cells by histology.
Figure 4
Figure 4
Distribution of atypical cells based on histology and Hepika test result. Data are presented in boxes and whiskers’ style, which represents the medians and ranges of the data. (Abbreviations: CC: carcinoma; CIN: cervical intraepithelial neoplasia (grade 1, 2, and 3); HK: Hepika (positive: +; negative: −); n: number of cases).
Figure 5
Figure 5
Distribution of atypical cells by Hepika test result. Data are presented in boxes and whiskers’ style, which represents the medians and ranges of the data. (Abbreviations: POS: positive; NEG: negative).
Figure 6
Figure 6
Distribution of complexes E6#p53 and E7#pRb optical density in relation to Hepika test result. Data are presented in boxes and whiskers’ style, which represents the medians and ranges of the data. (Abbreviations: POS: positive; NEG: negative).
See this image and copyright information in PMC

References

    1. WHO Human Papillomavirus (HPV) and Cervical Cancer. [(accessed on 30 January 2019)]; Available online: https://www.who.int/news-room/fact-sheets/detail/human-papillomavirus-(h....
    1. Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of inci-dence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018;68:394–424. doi: 10.3322/caac.21492. - DOI - PubMed
    1. Vizcaino A.P., Moreno V., Bosch F.X., Muñoz N., Barros-Dios X.M., Parkin D.M. International trends in the incidence of cervical cancer: I. Adenocarcinoma and adenosquamous cell carcinomas. Int. J. Cancer. 1998;75:536–545. doi: 10.1002/(SICI)1097-0215(19980209)75:4<536::AID-IJC8>3.0.CO;2-U. - DOI - PubMed
    1. Gustafsson L., Pontén J., Zack M., Adami H.-O. International incidence rates of invasive cervical cancer after introduction of cytological screening. Cancer Causes Control. 1997;8:755–763. doi: 10.1023/A:1018435522475. - DOI - PubMed
    1. Gustafsson L., Pontén J., Bergstrôm R., Adami H.-O. International incidence rates of invasive cervical cancer before cytological screening. Int. J. Cancer. 1997;71:159–165. doi: 10.1002/(SICI)1097-0215(19970410)71:2<159::AID-IJC6>3.0.CO;2-#. - DOI - PubMed

LinkOut - more resources